London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces ...
While presenting this year’s Nobel Prize in Physiology or Medicine to three immunologists who discovered and characterized regulatory T cells, committee chair Olle Kämpe, M.D., Ph.D., told the ...
TangGene names former GSK SVP Catherine Sohn as Senior Strategic Advisor, strengthening leadership as it advances a first-in-class in-vivo CD8⁺ Treg therapy. TangGene’s in-vivo CD8⁺ Treg approach has ...
Achievement of first significant research milestone triggers an option exercise payment of $10 million from AstraZeneca AstraZeneca will progress preclinical and clinical development of the selected ...
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...
The Chosun Ilbo on MSN
Sakaguchi: Cancer becomes ordinary via immunity in 20 years
Once an era arrives where cancer can be treated through immunity, cancer will no longer be a fearsome disease but an ordinary ...
Researchers have used TissueGnostics' advanced imaging and analysis tools to detect and quantify two cell types: the PD-1+ regulatory T cells (Treg)/PD-1+CD8+ cytotoxic T cells (CTL) ratio and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results